Yalong He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yalong He has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- An-An Yin
Department of Plastic and Reconstructive Surgery, Xijing Hospital, Air Force Medical University, Xi’an, China
6 shared publications - Wei Lin
Department of Neurosurgery, Xijing Hospital, Xi’an, China
5 shared publications Cheng Zou
State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi’an, China
4 shared publicationsGuangzhao Yang
Department of Neurosurgery, Xijing Hospital, The Fourth Military Medical University, Xi’an, China
4 shared publicationsMaorong Zhu
State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi’an, China
4 shared publicationsXiao Liu
Department of Neurosurgery, Xijing Hospital, The Fourth Military Medical University, Xi’an, China
4 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
Clinical associations of functionally prioritized synonymous mutations: a pan-cancer analysis
- 28 October 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
Open AccessClinical associations of functionally prioritized synonymous mutations: a pan-cancer analysis
- 1 June 2026
- Published by Springer Nature in MedScience
- Vol. 20 (3) , 473-482
CRISPR screening reveals NPC1L1 as a key driver of glioblastoma progression via cholesterol metabolic regulation
Glioblastoma (GBM), the most aggressive central nervous system (CNS) malignancy, currently lacks curative therapeutic options. While immunotherapy has revolutionized treatment for many cancers, GBM remains refractory to immune-based interventions due to the absence of effective immunotherapeutic targets. Here, through CRISPR screening, we identify Niemann–Pick C1-like 1 (NPC1L1) as a previously unrecognized key driver of GBM progression. Mechanistically, NPC1L1 modulates cholesterol metabolism to concurrently enhance tumor cell stemness and suppress CD8+ T-cell activation, thus inducing tumor progression. Notably, combined treatment with ezetimibe (NPC1L1 inhibitor) and anti-PD-1 antibody elicited potent antitumor activity in GBM orthotopic mouse models. Collectively, these findings establish NPC1L1 as a critical regulator of GBM pathogenesis, underscoring the translational potential of targeting NPC1L1-mediated cholesterol metabolism for developing novel GBM immunotherapies.
- 1 June 2026
- Published by Springer Nature in MedScience
- Vol. 20 (3) , 473-482
CRISPR screening reveals NPC1L1 as a key driver of glioblastoma progression via cholesterol metabolic regulation
Glioblastoma (GBM), the most aggressive central nervous system (CNS) malignancy, currently lacks curative therapeutic options. While immunotherapy has revolutionized treatment for many cancers, GBM remains refractory to immune-based interventions due to the absence of effective immunotherapeutic targets. Here, through CRISPR screening, we identify Niemann–Pick C1-like 1 (NPC1L1) as a previously unrecognized key driver of GBM progression. Mechanistically, NPC1L1 modulates cholesterol metabolism to concurrently enhance tumor cell stemness and suppress CD8+ T-cell activation, thus inducing tumor progression. Notably, combined treatment with ezetimibe (NPC1L1 inhibitor) and anti-PD-1 antibody elicited potent antitumor activity in GBM orthotopic mouse models. Collectively, these findings establish NPC1L1 as a critical regulator of GBM pathogenesis, underscoring the translational potential of targeting NPC1L1-mediated cholesterol metabolism for developing novel GBM immunotherapies.
- Open Access
- 1 May 2026
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 23 (6) , 2108-2138
Current Status and Evolution of Immunotherapy in Glioma Management
Gliomas, especially glioblastoma (GBM), are the most aggressive primary brain tumors, and their treatment faces multiple challenges. These challenges include incomplete surgical resection, the blood-brain barrier (BBB) that limits drug delivery, and an immunosuppressive tumor microenvironment (TME). Despite the "cold tumor" nature of gliomas, significant progress has been made in immunotherapy strategies. In this review, we focus on the following four strategies: 1) Cancer vaccines, especially personalized vaccines based on neoantigens, can activate specific immune responses; 2) Immune checkpoint inhibitors (ICIs) to reverse T cell exhaustion (e.g., anti-PD-1/PD-L1 antibodies); 3) Adoptive immune cell therapies, particularly chimeric antigen receptor T-cell (CAR-T) therapy, have shown encouraging results in preclinical trials; 4) Oncolytic viruses, which have dual roles of directly lysing tumor cells and stimulating immune responses. Immunotherapy offers a new paradigm to overcome the limitations of conventional glioma therapy. However, tumor heterogeneity, BBB limitation, target selection, and immunosuppressive microenvironment remain major obstacles. Future research should focus on developing combination therapies such as immunotherapy combined with radiotherapy, targeted therapy, exploring novel targets, and using biomarkers for patient stratification, which may help improve the survival outcomes of glioma patients. This review comprehensively evaluates the latest clinical progress of glioma immunotherapy, assesses the current limitations, and explores future directions.
- 1 May 2026
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 23 (6) , 2108-2138
Open AccessCurrent Status and Evolution of Immunotherapy in Glioma Management
Gliomas, especially glioblastoma (GBM), are the most aggressive primary brain tumors, and their treatment faces multiple challenges. These challenges include incomplete surgical resection, the blood-brain barrier (BBB) that limits drug delivery, and an immunosuppressive tumor microenvironment (TME). Despite the "cold tumor" nature of gliomas, significant progress has been made in immunotherapy strategies. In this review, we focus on the following four strategies: 1) Cancer vaccines, especially personalized vaccines based on neoantigens, can activate specific immune responses; 2) Immune checkpoint inhibitors (ICIs) to reverse T cell exhaustion (e.g., anti-PD-1/PD-L1 antibodies); 3) Adoptive immune cell therapies, particularly chimeric antigen receptor T-cell (CAR-T) therapy, have shown encouraging results in preclinical trials; 4) Oncolytic viruses, which have dual roles of directly lysing tumor cells and stimulating immune responses. Immunotherapy offers a new paradigm to overcome the limitations of conventional glioma therapy. However, tumor heterogeneity, BBB limitation, target selection, and immunosuppressive microenvironment remain major obstacles. Future research should focus on developing combination therapies such as immunotherapy combined with radiotherapy, targeted therapy, exploring novel targets, and using biomarkers for patient stratification, which may help improve the survival outcomes of glioma patients. This review comprehensively evaluates the latest clinical progress of glioma immunotherapy, assesses the current limitations, and explores future directions.
- 29 January 2026
- Published by Springer Nature in Neurosurgical Review
- Vol. 49 (1) , 170
Identifying four distinct prognostic trajectories using latent class growth analysis in moderate-severe TBI: a 10-year retrospective cohort study
Moderate-to-severe traumatic brain injury (msTBI) is associated with heterogeneous long-term outcomes, yet the dynamic trajectories of functional recovery remain poorly characterized. This study aimed to identify distinct prognostic trajectory subgroups and their risk factors in msTBI patients. A retrospective cohort study was conducted on msTBI patients admitted to our institution. Glasgow Outcome Scale (GOS) scores were assessed at discharge and at 3, 6, 12, and 24 months post-discharge. Latent class growth analysis (LCGA) was employed to identify distinct prognostic trajectories. Univariate analysis and multivariable ordinal regression models were used to identify factors associated with trajectory membership. A total of 401 patients were included in the final analysis. Four distinct prognostic trajectories were identified: (1) Catastrophic Outcome without Recovery (Trajectory 1), (2) Limited Improvement with Unfavorable Outcome (Trajectory 2), (3) Delayed but Sustained Favorable Recovery (Trajectory 3), and (4) Early Stable Favorable Outcome (Trajectory 4). Multivariable ordinal regression analysis identified admission and discharge levels of consciousness (LOC), discharge GOS score, age, and chronic comorbidities as significant independent factors associated with the prognostic trajectories. msTBI patients exhibit heterogeneous long-term recovery patterns that can be classified into four distinct trajectories. Early identification of trajectory membership through baseline clinical characteristics may facilitate personalized rehabilitation strategies and prognostic counseling.
- 29 January 2026
- Published by Springer Nature in Neurosurgical Review
- Vol. 49 (1) , 170
Identifying four distinct prognostic trajectories using latent class growth analysis in moderate-severe TBI: a 10-year retrospective cohort study
Moderate-to-severe traumatic brain injury (msTBI) is associated with heterogeneous long-term outcomes, yet the dynamic trajectories of functional recovery remain poorly characterized. This study aimed to identify distinct prognostic trajectory subgroups and their risk factors in msTBI patients. A retrospective cohort study was conducted on msTBI patients admitted to our institution. Glasgow Outcome Scale (GOS) scores were assessed at discharge and at 3, 6, 12, and 24 months post-discharge. Latent class growth analysis (LCGA) was employed to identify distinct prognostic trajectories. Univariate analysis and multivariable ordinal regression models were used to identify factors associated with trajectory membership. A total of 401 patients were included in the final analysis. Four distinct prognostic trajectories were identified: (1) Catastrophic Outcome without Recovery (Trajectory 1), (2) Limited Improvement with Unfavorable Outcome (Trajectory 2), (3) Delayed but Sustained Favorable Recovery (Trajectory 3), and (4) Early Stable Favorable Outcome (Trajectory 4). Multivariable ordinal regression analysis identified admission and discharge levels of consciousness (LOC), discharge GOS score, age, and chronic comorbidities as significant independent factors associated with the prognostic trajectories. msTBI patients exhibit heterogeneous long-term recovery patterns that can be classified into four distinct trajectories. Early identification of trajectory membership through baseline clinical characteristics may facilitate personalized rehabilitation strategies and prognostic counseling.
- Open Access
- 18 January 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 246, 117721
Targeted degradation of CD24 by a transferrin receptor-engaging bispecific degrader enhances antitumor immunity
- 18 January 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 246, 117721
Open AccessTargeted degradation of CD24 by a transferrin receptor-engaging bispecific degrader enhances antitumor immunity
- Open Access
- 7 February 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-18
Synergistic strategies for glioblastoma treatment: CRISPR-based multigene editing combined with immune checkpoint blockade
Glioblastoma (GBM) is a primary brain tumor known for its high levels of aggressiveness and resistance to current treatments such as radiotherapy and chemotherapy. As a result, there is a pressing need for innovative therapeutic approaches to combat GBM. Thus, we have developed an engineered multifunctional extracellular vesicle (EV) delivery system that offers an "all-in-one" strategy for GBM therapy. Our approach involved the use of genetic engineering to the long-lasting production of PD-1 and the brain-specific peptide angiopep-2 on the surface of EVs. These modified EVs were then utilized to rejuvenate exhausted CD8+ T cells blocking PD-L1, resulting in significant therapeutic benefits for GBM treatment. Furthermore, the EVs contained Cas9 protein and sgRNA for precise and minimally invasive gene therapy, which addressing the key barriers associated with in vivo CRISPR‒Cas9 gene editing treatment. The multigene editing of EVs resulted in efficient intratumor multisite gene editing (PLK1: 58.6%, VEGF: 52.7%), leading to the successful apoptosis of tumor cells in vivo and demonstrating an antiangiogenic effect. This research introduces a promising universal platform for combining immune checkpoint blockade therapy with gene editing treatment.
- 7 February 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-18
Open AccessSynergistic strategies for glioblastoma treatment: CRISPR-based multigene editing combined with immune checkpoint blockade
Glioblastoma (GBM) is a primary brain tumor known for its high levels of aggressiveness and resistance to current treatments such as radiotherapy and chemotherapy. As a result, there is a pressing need for innovative therapeutic approaches to combat GBM. Thus, we have developed an engineered multifunctional extracellular vesicle (EV) delivery system that offers an "all-in-one" strategy for GBM therapy. Our approach involved the use of genetic engineering to the long-lasting production of PD-1 and the brain-specific peptide angiopep-2 on the surface of EVs. These modified EVs were then utilized to rejuvenate exhausted CD8+ T cells blocking PD-L1, resulting in significant therapeutic benefits for GBM treatment. Furthermore, the EVs contained Cas9 protein and sgRNA for precise and minimally invasive gene therapy, which addressing the key barriers associated with in vivo CRISPR‒Cas9 gene editing treatment. The multigene editing of EVs resulted in efficient intratumor multisite gene editing (PLK1: 58.6%, VEGF: 52.7%), leading to the successful apoptosis of tumor cells in vivo and demonstrating an antiangiogenic effect. This research introduces a promising universal platform for combining immune checkpoint blockade therapy with gene editing treatment.
- 25 December 2023
- Published by Elsevier in Gas Science and Engineering
- Vol. 121, 205199
Establishment and application of propped hydraulic fracture conductivity theoretical model based on fracturing efficiency index
- 25 December 2023
- Published by Elsevier in Gas Science and Engineering
- Vol. 121, 205199
Establishment and application of propped hydraulic fracture conductivity theoretical model based on fracturing efficiency index
- 29 June 2023
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 165 (8) , 2237-2247
Machine learning algorithms for improved prediction of in-hospital outcomes after moderate-to-severe traumatic brain injury: a Chinese retrospective cohort study
Controversy remains high over the superiority of advanced machine learning (ML) algorithms to conventional logistic regression (LR) in the prediction of pr
- 29 June 2023
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 165 (8) , 2237-2247
Machine learning algorithms for improved prediction of in-hospital outcomes after moderate-to-severe traumatic brain injury: a Chinese retrospective cohort study
Controversy remains high over the superiority of advanced machine learning (ML) algorithms to conventional logistic regression (LR) in the prediction of pr
- 1 October 2022
- Published by Taylor & Francis in Epigenomics
- Vol. 14 (20) , 1233-1247
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated MGMT promoter
Aim: We aimed to identify potent CpG signatures predicting temozolomide (TMZ) response in glioblastomas (GBMs) that do not have the glioma-CpG island methylator phenotype (G-CIMP) but have a methyl... Plain language summary Glioblastomas that do not have the glioma-CpG island methylator phenotype (G-CIMP) but have a methylated promoter of the MGMT gene (meMGMT) show considerable variability in t...
- 1 October 2022
- Published by Taylor & Francis in Epigenomics
- Vol. 14 (20) , 1233-1247
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated MGMT promoter
Aim: We aimed to identify potent CpG signatures predicting temozolomide (TMZ) response in glioblastomas (GBMs) that do not have the glioma-CpG island methylator phenotype (G-CIMP) but have a methyl... Plain language summary Glioblastomas that do not have the glioma-CpG island methylator phenotype (G-CIMP) but have a methylated promoter of the MGMT gene (meMGMT) show considerable variability in t...
- Open Access
- 6 June 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-15
A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas
Objective. Alterations in the methylation state of pseudogenes may serve as clinically useful biomarkers of glioblastomas (GBMs) that do not have glioma-CpG island methylator phenotype (G-CIMP). Methods. Non-G-CIMP GBM datasets were included for evaluation, and a RISK-score signature was determined from the methylation state of pseudogene loci. Both bioinformatic and experimental analyses were performed for biological validation. Results. By integrating clinical information with DNA methylation microarray data, we screened a panel of eight CpGs from discovery cohorts of non-G-CIMP GBMs. Each CpG could accurately and independently predict the prognosis of patients under a treatment regime that combined radiotherapy (RT) and temozolomide (TMZ). The 8-CpG signature appeared to show opposite prognostic correlations between patients treated with RT/TMZ and those treated with RT monotherapy. The analyses further indicated that this signature had predictive value for TMZ efficacy because different survival benefits between RT/TMZ and RT therapies were observed in each risk subgroup. The incorporation of other risk factors, such as age and O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, with our pseudogene methylation signature could provide precise risk classification. In vitro experimental data revealed that two locus-specific pseudogenes (ZNF767P and CLEC4GP1) may modulate TMZ resistance via distinct mechanisms in GBM cells. Conclusion. The biologically and clinically relevant RISK-score signature, based on pseudogene methylation loci, may offer information for predicting TMZ responses of non-G-CIMP GBMs, that is independent from, but complementary to, MGMT-based approaches.
- 6 June 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-15
Open AccessA Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas
Objective. Alterations in the methylation state of pseudogenes may serve as clinically useful biomarkers of glioblastomas (GBMs) that do not have glioma-CpG island methylator phenotype (G-CIMP). Methods. Non-G-CIMP GBM datasets were included for evaluation, and a RISK-score signature was determined from the methylation state of pseudogene loci. Both bioinformatic and experimental analyses were performed for biological validation. Results. By integrating clinical information with DNA methylation microarray data, we screened a panel of eight CpGs from discovery cohorts of non-G-CIMP GBMs. Each CpG could accurately and independently predict the prognosis of patients under a treatment regime that combined radiotherapy (RT) and temozolomide (TMZ). The 8-CpG signature appeared to show opposite prognostic correlations between patients treated with RT/TMZ and those treated with RT monotherapy. The analyses further indicated that this signature had predictive value for TMZ efficacy because different survival benefits between RT/TMZ and RT therapies were observed in each risk subgroup. The incorporation of other risk factors, such as age and O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, with our pseudogene methylation signature could provide precise risk classification. In vitro experimental data revealed that two locus-specific pseudogenes (ZNF767P and CLEC4GP1) may modulate TMZ resistance via distinct mechanisms in GBM cells. Conclusion. The biologically and clinically relevant RISK-score signature, based on pseudogene methylation loci, may offer information for predicting TMZ responses of non-G-CIMP GBMs, that is independent from, but complementary to, MGMT-based approaches.